^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ET-901

    i
    Other names: ET-901, ATHENA CAR-T, TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T
    Associations

    News

    Trials
    Company:
    EdiGene
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    EDI-901-SLE01: A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, EdiGene Inc. | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    cyclophosphamide • fludarabine IV • ET-901
    7ms
    A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=12, Recruiting, EdiGene Inc.
    New P1 trial
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    cyclophosphamide • fludarabine IV • ET-901
    1year
    TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 30
    Enrollment open • Phase classification • Enrollment change • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • ET-901
    1year
    TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial • New P1/2 trial • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • ET-901